✦ LIBER ✦

Temporal patterns of response to d-penicillamine, hydroxychloroquine, and placebo in juvenile rheumatoid arthritis patients

✍ Scribed by Catherine Van Kerckhove; Edward H. Giannini; Daniel J. Lovell

Publisher: John Wiley and Sons
Year: 1988
Tongue: English
Weight: 654 KB
Volume: 31
Category: Article
ISSN: 0004-3591
DOI: 10.1002/art.1780311006

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Atacicept in patients with rheumatoid ar

Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: Results of a phase II, randomized, placebo-controlled trial

✍ R. F. van Vollenhoven; N. Kinnman; E. Vincent; S. Wax; J. Bathon 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 293 KB 👁 2 views

Atacicept in patients with rheumatoid ar

Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: Results of a phase II, randomized, placebo-controlled, dose-finding trial

✍ M. C. Genovese; N. Kinnman; G. de La Bourdonnaye; C. Pena Rossi; P. P. Tak 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 242 KB 👁 2 views

Safety and efficacy of ocrelizumab in pa

Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: Results of a forty-eight–week randomized, double-blind, placebo-controlled, parallel-group phase III trial

✍ W. Rigby; H.-P. Tony; K. Oelke; B. Combe; A. Laster; C. A. von Muhlen; E. Fishel 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 112 KB 👁 2 views

Safety and efficacy of ocrelizumab in pa

Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: Results of a forty-eight–week randomized, double-blind, placebo-controlled, parallel-group phase III trial

✍ P. P. Tak; P. J. Mease; M. C. Genovese; J. Kremer; B. Haraoui; Y. Tanaka; C. O. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 199 KB 👁 2 views

Phase IIb dose-ranging study of the oral

Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs

✍ Roy Fleischmann; Maurizio Cutolo; Mark C. Genovese; Eun Bong Lee; Keith S. Kanik 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 424 KB 👁 4 views

Modulation of RANKL and osteoprotegerin

Modulation of RANKL and osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis in response to disease‐modifying antirheumatic drug treatment and correlation with radiologic outcome

✍ Haynes, David ;Crotti, Tania ;Weedon, Helen ;Slavotinek, John ;Au, Virginia ;Col 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 881 KB